Cannabis Concept(BK4557),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4557 Cannabis Concept

Not Yet Opened 05-21 16:00:00 EDT

282.99

-2.57

-0.90%

High286.30	Low282.46	Vol44.39M
Open285.55	D1 Closing285.56	Amplitude1.35%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O292.94M	T/O Rate--	Tradable Shares0.00
P/B2.031722	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4557","market":"US","secType":"PLATE","nameCN":"Cannabis Concept","latestPrice":282.98972,"timestamp":1716321599999,"preClose":285.5624,"halted":0,"volume":44394606,"delay":0,"changeRate":-0.009009,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-2.572693,"latestTime":"05-21 16:00:00 EDT","open":285.5526,"high":286.30472,"low":282.45956,"amount":292938450.736547,"amplitude":0.013465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1716384600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.031722,"peRate":-36.671378,"turnoverRate":0.014409,"increases":4,"decrements":15,"flats":0,"marketCap":39599445650.875,"floatMarketCap":33629635212.125},"requestUrl":"/m/hq/s/BK4557/","defaultTab":"news","newsList":[{"id":"2437269352","title":"3 Cannabis Stocks That Could Be Millionaire-Makers: May Edition","url":"https://stock-news.laohu8.com/highlight/detail?id=2437269352","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2437269352?lang=en_us&edition=fundamental","pubTime":"2024-05-22 19:25","pubTimestamp":1716377100,"startTime":"0","endTime":"0","summary":"Cannabis stocks to buy are surging after the DOJ proposed reclassifying marijuana, signaling a promising future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/3-cannabis-stocks-that-could-be-millionaire-makers-may-edition/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437268535","title":"H.C. Wainwright Remains a Hold on Durect (DRRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437268535","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437268535?lang=en_us&edition=fundamental","pubTime":"2024-05-22 18:27","pubTimestamp":1716373637,"startTime":"0","endTime":"0","summary":"In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Durect (DRRX – Research Report). The company’s shares closed y...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-hold-on-durect-drrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-hold-on-durect-drrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437509822","title":"Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol","url":"https://stock-news.laohu8.com/highlight/detail?id=2437509822","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2437509822?lang=en_us&edition=fundamental","pubTime":"2024-05-22 18:00","pubTimestamp":1716372000,"startTime":"0","endTime":"0","summary":"RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has granted approval for the Company's Abbreviated New Drug Application  for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir HFA  Inhalation Aerosol.Amphastar's CEO and President, Dr. Jack Zhang, commented: \"Our first generic inhalation product's approval reflects both our technological and manufacturing ability. While patients can benefit from increased access to this combination drug product, we are proud to manufacture the finished product in the United States, a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/m89Ov9ix.Pufiem9f_dC8A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/90e521a3fdf957b772eef6bc052f6552","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/m89Ov9ix.Pufiem9f_dC8A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/90e521a3fdf957b772eef6bc052f6552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amphastar-receives-fda-approval-albuterol-100000786.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437547628","title":"Cronos Group Inc. Stock Falls Tuesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2437547628","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2437547628?lang=en_us&edition=fundamental","pubTime":"2024-05-22 05:27","pubTimestamp":1716326820,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Cronos Group Inc.  dropped 0.36% to $2.77 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.22% to 16,832.62 and the Dow Jones Industrial Average  rising 0.17% to 39,872.99.This was the stock's third consecutive day of losses.Cronos Group Inc. closed $0.37 below its 52-week high , which the company achieved on May 16th.Trading volume  remained 2.3 million below its 50-day average volume of 3.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled May 21, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2437478643","title":"FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2437478643","media":"CNW Group","top":-1,"share":"https://ttm.financial/m/news/2437478643?lang=en_us&edition=fundamental","pubTime":"2024-05-22 04:01","pubTimestamp":1716321660,"startTime":"0","endTime":"0","summary":"The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan's LPT-CBD release technology, marking a key step in the advancement of non-opioid pain management. The meeting with the FDA has been set for July 31, 2024, where Innocan will present its preclinical results and proposed clinical development plan. This meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain.Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: LPTCBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-granted-innocan-pharma-meeting-200100839.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437429807","title":"Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2437429807","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437429807?lang=en_us&edition=fundamental","pubTime":"2024-05-22 01:55","pubTimestamp":1716314114,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437440592","title":"Dr. Reddy’s Clinches Biosimilar Deal with Alvotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2437440592","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437440592?lang=en_us&edition=fundamental","pubTime":"2024-05-21 23:58","pubTimestamp":1716307135,"startTime":"0","endTime":"0","summary":"Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has secured a strategic deal with Alvotech to in-license and commerc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dr-reddys-clinches-biosimilar-deal-with-alvotech?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dr-reddys-clinches-biosimilar-deal-with-alvotech?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437344063","title":"Dr. Reddy’s Subsidiary Faces GST Penalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2437344063","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437344063?lang=en_us&edition=fundamental","pubTime":"2024-05-21 23:58","pubTimestamp":1716307114,"startTime":"0","endTime":"0","summary":"Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s wholly-owned subsidiary, Aurigene Oncology Limited, has been ordered by the GST A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dr-reddys-subsidiary-faces-gst-penalty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dr-reddys-subsidiary-faces-gst-penalty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437561425","title":"Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla","url":"https://stock-news.laohu8.com/highlight/detail?id=2437561425","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437561425?lang=en_us&edition=fundamental","pubTime":"2024-05-21 23:20","pubTimestamp":1716304800,"startTime":"0","endTime":"0","summary":"Exelixis, Inc. EXEL entered into a settlement agreement with Cipla, which was looking to market a generic version of Cabometyx .Cabometyx is Exelixis’ lead drug. The settlement agreement resolves two patent litigations brought by Exelixis in response to Cipla’s abbreviated new drug application .The ANDA is seeking approval to market generic versions of Cabometyx tablets prior to the expiration of the applicable patents. The first case relates to Cipla’s ANDA for a 60 mg cabozantinib dosage strength. This case was filed on Mar 16, 2023.The second case was filed on May 9, 2024, and relates to a recent amendment to Cipla’s ANDA for the primary purpose of seeking additional approval for 20 mg and 40 mg cabozantinib dosage strengths.Per the settlement, Exelixis will grant Cipla a license to market generic versions of Cabometyx in the United States beginning on Jan 1, 2031, upon FDA approval and subject to conditions and exceptions common to agreements of this type.Both parties will terminat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exelixis-exel-settles-cabometyx-patent-152000423.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437444031","title":"Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2437444031","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437444031?lang=en_us&edition=fundamental","pubTime":"2024-05-21 23:17","pubTimestamp":1716304625,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437446744","title":"Marijuana rescheduling proposed rule comments due by July 22","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446744","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437446744?lang=en_us&edition=fundamental","pubTime":"2024-05-21 23:04","pubTimestamp":1716303888,"startTime":"0","endTime":"0","summary":"In a notice of proposed rulemaking published in the Federal Register, the Department of Justice said it will accept public comments on the potential rescheduling of marijuana to a Schedule III from a ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1466091682/image_1466091682.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1466091682/image_1466091682.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108876-marijuana-rescheduling-proposed-rule-comments-by-july-22","is_publish_highlight":false,"gpt_icon":0},{"id":"2437449293","title":"Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2437449293","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437449293?lang=en_us&edition=fundamental","pubTime":"2024-05-21 22:40","pubTimestamp":1716302449,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437446408","title":"BUZZ-Durect up on FDA's 'breakthrough therapy' tag for liver disease treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2437446408","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437446408?lang=en_us&edition=fundamental","pubTime":"2024-05-21 22:17","pubTimestamp":1716301041,"startTime":"0","endTime":"0","summary":"** Shares of drugmaker Durect Corp    rise 3.8% to $1.1    ** U.S. FDA has granted \"breakthrough therapy\" designation  to DRRX's treatment for patients with severe alcohol-associated hepatitis    ** AH is an acute form of liver disease associated with long-term heavy alcohol intake, often following a recent period of increased consumption   ** Company plans to confirm the efficacy and safety of the treatment candidate, larsucosterol, in a registrational late-stage trial    ** BTD is meant to speed up the development and review of drugs to treat a serious condition or unmet medical need    ** Including session's gain, stock up more than 80% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437844656","title":"DURECT gets FDA breakthrough therapy status for larsucosterol","url":"https://stock-news.laohu8.com/highlight/detail?id=2437844656","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437844656?lang=en_us&edition=fundamental","pubTime":"2024-05-21 22:10","pubTimestamp":1716300608,"startTime":"0","endTime":"0","summary":"DURECT  has received FDA breakthrough therapy designation for its drug candidate larsucosterol in the treatment of severe alcohol-related hepatitis. The drug developer plans to present additional details on Phase 2 data for the drug at the upcoming European Association for the Study of the Liver Congress, to be held in Milan on June 8, according to a statement.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108832-durect-gets-fda-breakthrough-therapy-status-for-larsucosterol","is_publish_highlight":false,"gpt_icon":0},{"id":"2437445434","title":"Taro Pharmaceutical Reports Strong Fiscal Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2437445434","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2437445434?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:59","pubTimestamp":1716299968,"startTime":"0","endTime":"0","summary":"Taro Pharmaceutical (TARO) has released an update. Taro Pharmaceutical Industries Ltd. reported a robust financial performance for the fiscal year ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taro-pharmaceutical-reports-strong-fiscal-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taro-pharmaceutical-reports-strong-fiscal-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2437448340","title":"Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2437448340","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437448340?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:20","pubTimestamp":1716297602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437744812","title":"PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2437744812","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2437744812?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:00","pubTimestamp":1716296400,"startTime":"0","endTime":"0","summary":"Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value. MyMD Pharmaceuticals, Inc. , a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol  and is being developed to address and imp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharmacyte-biotech-makes-7-million-130000679.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437707448","title":"MyMD Pharmaceuticals Secures Strategic Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2437707448","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2437707448?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:00","pubTimestamp":1716296400,"startTime":"0","endTime":"0","summary":"Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front. BALTIMORE, May 21, 2024----MyMD Pharmaceuticals, Inc.  , a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. , a clinical-stage biotechnology company developing cellular therapies for cancer and diabetes. An additional $7 million was raised from existing MyMD shareholders participating in the offerings. The closings of the two private placements are each subject to customary closing conditions and are both expected to occur on or around May 22, 2024.Under the terms of the purchase agreement for MyMD’s Series F-1 Preferred Stock financing round, existing shareholders will receive 5","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IpEZ2wZReruTSf6x88ZIdw--~B/aD0yMTE7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cb451653bbe4d54d1c37f00cd266c4d2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IpEZ2wZReruTSf6x88ZIdw--~B/aD0yMTE7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cb451653bbe4d54d1c37f00cd266c4d2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mymd-pharmaceuticals-secures-strategic-investments-130000804.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2437412711","title":"Alvotech and Dr. Reddy’s collaborate for commercialization of denosumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2437412711","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437412711?lang=en_us&edition=fundamental","pubTime":"2024-05-21 20:39","pubTimestamp":1716295159,"startTime":"0","endTime":"0","summary":"Alvotech  and Dr. Reddy’s Laboratories SA  announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva . Dr. Reddy’s gets exclusive commercialization rights in the United States as well as semi-exclusive rights in Europe and United Kingdom  Alvotech will be responsible for development and manufacturing of the product. Source: Press Release","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4108747-alvotech-and-dr-reddys-collaborate-for-commercialization-of-denosumab","is_publish_highlight":false,"gpt_icon":0},{"id":"2437414038","title":"BRIEF-DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2437414038","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437414038?lang=en_us&edition=fundamental","pubTime":"2024-05-21 20:30","pubTimestamp":1716294633,"startTime":"0","endTime":"0","summary":"May 21  - DURECT Corp   :   * DURECT CORPORATION RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS   * DURECT CORP -DURECT PLANS TO CONFIRM EFFICACY AND SAFETY OF LARSUCOSTEROL IN A REGISTRATIONAL PHASE 3 CLINICAL TRIALSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0154},{"period":"1month","weight":0.0731},{"period":"3month","weight":0.0687},{"period":"6month","weight":0.1678},{"period":"1year","weight":0.2688},{"period":"ytd","weight":0.1179}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4557","nameEN":"BK4557"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cannabis Concept(BK4557),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cannabis Concept(BK4557) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cannabis Concept,BK4557,Cannabis Concept股票,Cannabis Concept股票老虎,Cannabis Concept股票老虎国际,Cannabis Concept行情,Cannabis Concept股票行情,Cannabis Concept股价,Cannabis Concept股市,Cannabis Concept股票价格,Cannabis Concept股票交易,Cannabis Concept股票购买,Cannabis Concept股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cannabis Concept(BK4557),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cannabis Concept(BK4557) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}